301617.SZ
Shandong Boyuan Pharmaceutical & Chemical Co. Ltd.
SZSE · C 制造业 · CN
CNY 48.11
−2.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.5B | 1.3B | 1.0B | 798.5M |
| Cost of Revenue | 1.2B | 1.2B | 999.1M | 739.2M | 517.6M |
| Gross Profit | 295.8M | 296.1M | 328.8M | 285.9M | 280.9M |
| Operating Expenses | |||||
| R&D Expense | 49.9M | 52.7M | 41.3M | 35.7M | 30.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 34.0M | 33.3M | 31.2M | 28.8M | 31.5M |
| Selling & Marketing Expense | 12.8M | 13.0M | 11.7M | 8.7M | 5.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 99.7M | 102.7M | 89.6M | 77.4M | 71.0M |
| Cost and Expenses | 1.3B | 1.3B | 1.1B | 816.6M | 588.6M |
| Operating Income (EBIT) | 204.6M | 199.6M | 244.5M | 208.3M | 205.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 200.4M | 196.0M | 244.4M | 207.9M | 201.3M |
| Income Tax Expense | 26.1M | 23.7M | 31.5M | 25.8M | 25.0M |
| Bottom Line | |||||
| Net Income | 174.3M | 172.3M | 212.8M | 182.1M | 176.3M |
| Earnings from Cont. Ops | 174.3M | 172.3M | 212.8M | 182.1M | 176.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 174.3M | 172.3M | 212.8M | 182.1M | 176.3M |
| Per Share | |||||
| Basic EPS | CN¥1.30 | CN¥1.29 | CN¥2.12 | CN¥2.36 | CN¥2.29 |
| Diluted EPS | CN¥1.30 | CN¥1.29 | CN¥2.12 | CN¥2.36 | CN¥2.29 |
| Revenue Per Share | CN¥11.49 | CN¥10.97 | CN¥13.23 | CN¥13.29 | CN¥10.37 |
| Shares | |||||
| Basic Shares Outstanding | 133.6M | 133.6M | 100.4M | 77.2M | 77.0M |
| Diluted Shares Outstanding | 133.6M | 133.6M | 100.4M | 77.2M | 77.0M |
| Profitability Metrics | |||||
| EBITDA | — | 234.0M | 273.5M | 232.5M | 227.6M |
| D&A | — | 34.5M | 29.0M | 24.2M | 21.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026